Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates

Pavlo Gilchuk, Chad Mire, Joan B. Geisbert, Krystle N. Agans, Daniel J. Deer, Robert Cross, James C. Slaughter, Andrew I. Flyak, Jeremy Mani, Michael H. Pauly, Jesus Velasco, Kevin J. Whaley, Larry Zeitlin, Thomas Geisbert, James E. Crowe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The 2013-2016 Ebola virus disease (EVD) epidemics in West Africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. Monoclonal antibodies (mAbs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. Data about efficacy of human mAb monotherapy against filovirus infections in preclinical nonhuman primate models are limited. Methods: Previously, we described a large panel of human mAbs derived from the circulating memory B cells from Bundibugyo virus (BDBV) infection survivors that bind to the surface glycoprotein (GP) of the virus. We tested one of these neutralizing mAbs that recognized the glycan cap of the GP, designated mAb BDBV289, as monotherapy in rhesus macaques. Results: We found that recombinant mAb BDBV289-N could confer up to 100% protection to BDBV-infected rhesus macaques when treatment was initiated as late as 8 days after virus challenge. Protection was associated with survival and decreased viremia levels in the blood of treated animals. Conclusions: These findings define the efficacy of monotherapy of lethal BDBV infection with a glycan cap-specific mAb and identify a candidate mAb therapeutic molecule that could be included in antibody cocktails for prevention or treatment of ebolavirus infections.

Original languageEnglish (US)
Pages (from-to)S565-S573
JournalThe Journal of infectious diseases
Volume218
Issue number5
DOIs
StatePublished - Nov 22 2018

Fingerprint

Virus Diseases
Primates
Monoclonal Antibodies
Viruses
Macaca mulatta
Polysaccharides
Ebola Hemorrhagic Fever
Ebolavirus
Western Africa
Viremia
Membrane Glycoproteins
Infection
Neutralizing Antibodies
Glycoproteins
B-Lymphocytes
Therapeutics
Survival
Antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. / Gilchuk, Pavlo; Mire, Chad; Geisbert, Joan B.; Agans, Krystle N.; Deer, Daniel J.; Cross, Robert; Slaughter, James C.; Flyak, Andrew I.; Mani, Jeremy; Pauly, Michael H.; Velasco, Jesus; Whaley, Kevin J.; Zeitlin, Larry; Geisbert, Thomas; Crowe, James E.

In: The Journal of infectious diseases, Vol. 218, No. 5, 22.11.2018, p. S565-S573.

Research output: Contribution to journalArticle

Gilchuk, P, Mire, C, Geisbert, JB, Agans, KN, Deer, DJ, Cross, R, Slaughter, JC, Flyak, AI, Mani, J, Pauly, MH, Velasco, J, Whaley, KJ, Zeitlin, L, Geisbert, T & Crowe, JE 2018, 'Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates', The Journal of infectious diseases, vol. 218, no. 5, pp. S565-S573. https://doi.org/10.1093/infdis/jiy295
Gilchuk, Pavlo ; Mire, Chad ; Geisbert, Joan B. ; Agans, Krystle N. ; Deer, Daniel J. ; Cross, Robert ; Slaughter, James C. ; Flyak, Andrew I. ; Mani, Jeremy ; Pauly, Michael H. ; Velasco, Jesus ; Whaley, Kevin J. ; Zeitlin, Larry ; Geisbert, Thomas ; Crowe, James E. / Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. In: The Journal of infectious diseases. 2018 ; Vol. 218, No. 5. pp. S565-S573.
@article{e8ac2fe4572b4e378ecfa7e53dca0202,
title = "Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates",
abstract = "Background: The 2013-2016 Ebola virus disease (EVD) epidemics in West Africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. Monoclonal antibodies (mAbs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. Data about efficacy of human mAb monotherapy against filovirus infections in preclinical nonhuman primate models are limited. Methods: Previously, we described a large panel of human mAbs derived from the circulating memory B cells from Bundibugyo virus (BDBV) infection survivors that bind to the surface glycoprotein (GP) of the virus. We tested one of these neutralizing mAbs that recognized the glycan cap of the GP, designated mAb BDBV289, as monotherapy in rhesus macaques. Results: We found that recombinant mAb BDBV289-N could confer up to 100{\%} protection to BDBV-infected rhesus macaques when treatment was initiated as late as 8 days after virus challenge. Protection was associated with survival and decreased viremia levels in the blood of treated animals. Conclusions: These findings define the efficacy of monotherapy of lethal BDBV infection with a glycan cap-specific mAb and identify a candidate mAb therapeutic molecule that could be included in antibody cocktails for prevention or treatment of ebolavirus infections.",
author = "Pavlo Gilchuk and Chad Mire and Geisbert, {Joan B.} and Agans, {Krystle N.} and Deer, {Daniel J.} and Robert Cross and Slaughter, {James C.} and Flyak, {Andrew I.} and Jeremy Mani and Pauly, {Michael H.} and Jesus Velasco and Whaley, {Kevin J.} and Larry Zeitlin and Thomas Geisbert and Crowe, {James E.}",
year = "2018",
month = "11",
day = "22",
doi = "10.1093/infdis/jiy295",
language = "English (US)",
volume = "218",
pages = "S565--S573",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates

AU - Gilchuk, Pavlo

AU - Mire, Chad

AU - Geisbert, Joan B.

AU - Agans, Krystle N.

AU - Deer, Daniel J.

AU - Cross, Robert

AU - Slaughter, James C.

AU - Flyak, Andrew I.

AU - Mani, Jeremy

AU - Pauly, Michael H.

AU - Velasco, Jesus

AU - Whaley, Kevin J.

AU - Zeitlin, Larry

AU - Geisbert, Thomas

AU - Crowe, James E.

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Background: The 2013-2016 Ebola virus disease (EVD) epidemics in West Africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. Monoclonal antibodies (mAbs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. Data about efficacy of human mAb monotherapy against filovirus infections in preclinical nonhuman primate models are limited. Methods: Previously, we described a large panel of human mAbs derived from the circulating memory B cells from Bundibugyo virus (BDBV) infection survivors that bind to the surface glycoprotein (GP) of the virus. We tested one of these neutralizing mAbs that recognized the glycan cap of the GP, designated mAb BDBV289, as monotherapy in rhesus macaques. Results: We found that recombinant mAb BDBV289-N could confer up to 100% protection to BDBV-infected rhesus macaques when treatment was initiated as late as 8 days after virus challenge. Protection was associated with survival and decreased viremia levels in the blood of treated animals. Conclusions: These findings define the efficacy of monotherapy of lethal BDBV infection with a glycan cap-specific mAb and identify a candidate mAb therapeutic molecule that could be included in antibody cocktails for prevention or treatment of ebolavirus infections.

AB - Background: The 2013-2016 Ebola virus disease (EVD) epidemics in West Africa highlighted a need for effective therapeutics for treatment of the disease caused by filoviruses. Monoclonal antibodies (mAbs) are promising therapeutic candidates for prophylaxis or treatment of virus infections. Data about efficacy of human mAb monotherapy against filovirus infections in preclinical nonhuman primate models are limited. Methods: Previously, we described a large panel of human mAbs derived from the circulating memory B cells from Bundibugyo virus (BDBV) infection survivors that bind to the surface glycoprotein (GP) of the virus. We tested one of these neutralizing mAbs that recognized the glycan cap of the GP, designated mAb BDBV289, as monotherapy in rhesus macaques. Results: We found that recombinant mAb BDBV289-N could confer up to 100% protection to BDBV-infected rhesus macaques when treatment was initiated as late as 8 days after virus challenge. Protection was associated with survival and decreased viremia levels in the blood of treated animals. Conclusions: These findings define the efficacy of monotherapy of lethal BDBV infection with a glycan cap-specific mAb and identify a candidate mAb therapeutic molecule that could be included in antibody cocktails for prevention or treatment of ebolavirus infections.

UR - http://www.scopus.com/inward/record.url?scp=85057209498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057209498&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiy295

DO - 10.1093/infdis/jiy295

M3 - Article

C2 - 29982718

AN - SCOPUS:85057209498

VL - 218

SP - S565-S573

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -